Thyroid Carcinoma Clinical Trial
Official title:
A Study Into the Effect of Seprafilm on Post Operative Adhesions After Open Total Thyroidectomy.
The investigators intend to determine the role of Seprafilm, a popular anti-adhesive agent in minimising internal adhesion formation in the neck after thyroid surgery and therefore reduce swallowing discomfort experienced by patients after surgery.
Thyroid surgery not only constitutes one of the main pillars in the treatment of thyroid
cancers, but is also employed in the management of symptomatic goitres. Occasionally, it is
mandated in patients with thyrotoxicosis refractory to medical therapy. While thyroid
surgery can be performed with low risks such that patients rarely have to stay beyond three
days in hospital, the track record of thyroid surgery is somewhat blemished by the
unfortunate side effects associated with the neck scarring after thyroid surgery. Not
uncommonly, patients experience discomfort in the neck region after thyroid surgery; in the
extreme of cases, patients may even complain of a lifelong pulling sensation in the neck
area during eating.
The anti-adhesive properties of Seprafilm are well established in animal studies and
affirmed by clinical observations in abdominal surgeries that utilize this material. Thus,
Seprafilm is routinely used in instances when a surgeon foresees a need to perform abdominal
surgery on the same patient in future, or during the fashioning of a temporary stoma. The
safety profile of Seprafilm in thyroidectomy has also been shown by a recent study conducted
by a group of clinicians in Seoul.
We postulate that the application of Seprafilm to the surgical wound towards the end of a
thyroidectomy significantly reduces internal adhesion formation in the neck region. By
achieving this objective, we hope to improve patients' satisfaction with thyroid surgery in
terms of ease of swallowing after surgery.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02658513 -
Evaluation of Lancet Blood Sampling for Radioiodine Dosimetry in Thyroid Cancer
|
||
Withdrawn |
NCT01707056 -
The Effect of Coffee on the Absorption of Thyroid Hormone in Patients With Thyroid Carcinoma
|
N/A | |
Completed |
NCT00215605 -
Study of XL184 (Cabozantinib) in Adults With Advanced Malignancies
|
Phase 1 | |
Completed |
NCT06439745 -
More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
|
||
Terminated |
NCT04327999 -
Effect of Artificial Tears on Radioiodine Levels in the Nasolacrimal Duct System
|
Phase 2 | |
Completed |
NCT02194920 -
Parathyroid Reimplantation in Forearm Subcutaneous Tissue During Thyroidectomy: a Simple Way to Avoid Ipoparathyroidism and Evaluate Graft Function
|
N/A | |
Enrolling by invitation |
NCT06095362 -
Thyroid Cancer and Central Lymph Node Metastases Detection Using Bevacizumab-IRDye800CW
|
Phase 1 | |
Not yet recruiting |
NCT05949424 -
OPTI - DOSE: Optimal Dosing of Oral Anticancer Drugs in Older Adults
|
Phase 4 | |
Active, not recruiting |
NCT02145143 -
Enhancing Radioiodine (RAI) Incorporation Into BRAF Mutant, RAI-Refractory Thyroid Cancers With the BRAF Inhibitor Vemurafenib: A Pilot Study
|
N/A | |
Recruiting |
NCT00749697 -
Radioiodine Dosimetry Protocol for Thyroid Cancer Metastases
|
N/A | |
Enrolling by invitation |
NCT04411290 -
Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
|
||
Completed |
NCT01813136 -
Phase II Study of the Optimal Scheme of Administration of Pazopanib in Thyroid Carcinoma
|
Phase 2 | |
Recruiting |
NCT05668962 -
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
|
Phase 2 | |
Active, not recruiting |
NCT02185560 -
Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
|
||
Completed |
NCT04462471 -
Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers
|
Phase 1 | |
Completed |
NCT01433809 -
Biomarkers to Distinguish Benign From Malignant Thyroid Neoplasm
|
N/A | |
Recruiting |
NCT00929318 -
Influence of Thyroid Hormones on the Woundhealing Process
|
N/A | |
Completed |
NCT05178186 -
Impact of the COVID-19 Pandemic on Surgery for Thyroid Cancer
|
N/A | |
Completed |
NCT02773667 -
Renal Tracer Elimination in Thyroid Cancer Patients Treated With 131-Iodine
|
||
Not yet recruiting |
NCT00993837 -
Feasibility of Endoscopic Thyroidectomy for Thyroid Carcinoma
|
N/A |